Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
2002

AKT Activation in Breast Cancer and Its Impact on Treatment Outcomes

Sample size: 93 publication Evidence: moderate

Author Information

Author(s): Pérez-Tenorio G, Stål O

Primary Institution: Linköping University

Hypothesis

The study aimed to determine whether the expression and activation of Akt-1 are related to prognostic markers and survival in breast cancer patients treated with endocrine therapy.

Conclusion

The activation of Akt may have prognostic relevance in breast cancer, as pAkt positive patients were more prone to relapse with distant metastasis.

Supporting Evidence

  • pAkt was associated with lower S-phase fraction (P=0.001).
  • pAkt positive patients were more prone to relapse with distant metastasis (P=0.004).
  • Heregulin β1 was found mainly in oestrogen receptor negative cases (P=0.026).
  • Heregulin β1 expression was inversely associated with lymph node status (P=0.005).

Takeaway

This study found that a protein called pAkt can help predict if breast cancer patients will have a relapse after treatment.

Methodology

The study analyzed the expression and activation of Akt-1 in breast cancer patients using flow cytometry and immunohistochemistry.

Limitations

The study may be undersized to detect significant differences in some associations due to the small number of tumors overexpressing erbB-2.

Participant Demographics

Patients were aged 35-49 years and treated with tamoxifen and/or goserelin.

Statistical Information

P-Value

P=0.004

Confidence Interval

95% CI, 1.0–6.2

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600126

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication